The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
暂无分享,去创建一个
D. Sheehan | B. Rive | H. Loft | N. Danchenko | I. Florea | E. Merikle | M. Brignone | P. Jacobsen
[1] JAMA. , 2019, JAMA.
[2] M. Thase,et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults , 2016, European Neuropsychopharmacology.
[3] D. Sheehan,et al. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors , 2015, Human psychopharmacology.
[4] M. Trivedi,et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. , 2015, The Journal of clinical psychiatry.
[5] M. Trivedi,et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. , 2015, The Journal of clinical psychiatry.
[6] A. Heinemann,et al. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial. , 2015, JAMA psychiatry.
[7] Ronald C Kessler,et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). , 2015, The Journal of clinical psychiatry.
[8] S. Montgomery,et al. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study , 2015, Current medical research and opinion.
[9] M. Trivedi,et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD , 2015, Psychopharmacology.
[10] S. Kennedy,et al. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial , 2014, Psychiatry Research.
[11] S. Montgomery,et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine , 2014, Human psychopharmacology.
[12] C. Gommoll,et al. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials , 2014, International clinical psychopharmacology.
[13] R. McIntyre,et al. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults , 2014, The international journal of neuropsychopharmacology.
[14] C. Olsen,et al. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder , 2014, International clinical psychopharmacology.
[15] J. Endicott,et al. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder , 2014, CNS Spectrums.
[16] D. Sheehan,et al. A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder , 2013, Journal of clinical psychopharmacology.
[17] A. Gnanasakthy,et al. Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder , 2014, Neuropsychiatric disease and treatment.
[18] S. Montgomery,et al. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study , 2013, International clinical psychopharmacology.
[19] G. Freedman,et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010 , 2013, PLoS medicine.
[20] C. Gommoll,et al. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. , 2013, The Journal of clinical psychiatry.
[21] M. Thase,et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. , 2013, The international journal of neuropsychopharmacology.
[22] Yinzhong Chen,et al. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder , 2013, Current medical research and opinion.
[23] V. Pérez,et al. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. , 2012, Journal of affective disorders.
[24] D. Sheehan,et al. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies , 2012, International clinical psychopharmacology.
[25] M. Thase,et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. , 2012, The Journal of clinical psychiatry.
[26] D. Baldwin,et al. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD) , 2012, European Neuropsychopharmacology.
[27] Cornelius Katona,et al. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder , 2012, International clinical psychopharmacology.
[28] M. Zimmerman,et al. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? , 2012, The Journal of clinical psychiatry.
[29] C. Bundgaard,et al. Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder , 2012, Journal of Pharmacology and Experimental Therapeutics.
[30] M. Thase,et al. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol , 2012, Human psychopharmacology.
[31] C. Soares,et al. Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis , 2012, International clinical psychopharmacology.
[32] B. Dunlop,et al. Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo , 2011, Journal of clinical psychopharmacology.
[33] R. Lam,et al. Clinical effectiveness: the importance of psychosocial functioning outcomes. , 2011, Journal of affective disorders.
[34] V. Pérez,et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder , 2011, The international journal of neuropsychopharmacology.
[35] Thomas Ruhland,et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. , 2011, Journal of medicinal chemistry.
[36] D. Sheehan,et al. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale , 2011, International clinical psychopharmacology.
[37] J. Modell,et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR , 2010, Journal of psychopharmacology.
[38] S. Stahl,et al. Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial , 2010, Journal of clinical psychopharmacology.
[39] I. Gilaberte,et al. Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study , 2010, European Psychiatry.
[40] M. Thase,et al. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. , 2009, The Journal of clinical psychiatry.
[41] R. Lennox,et al. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning , 2009, International clinical psychopharmacology.
[42] Patrick E. McKnight,et al. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. , 2009, Clinical psychology review.
[43] M. Frye,et al. The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder , 2009, Psychiatry Research.
[44] M. Posternak,et al. Remission in depressed outpatients: more than just symptom resolution? , 2008, Journal of psychiatric research.
[45] L. Judd,et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. , 2008, Journal of affective disorders.
[46] D. Sheehan,et al. Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale , 2008, International clinical psychopharmacology.
[47] Maurizio Fava,et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. , 2008, The American journal of psychiatry.
[48] Vikram Patel,et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys , 2007, The Lancet.
[49] Mark D. Miller,et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study , 2007, British Journal of Psychiatry.
[50] M. Posternak,et al. Discordance between self-reported symptom severity and psychosocial functioning ratings in depressed outpatients: Implications for how remission from depression should be defined , 2006, Psychiatry Research.
[51] J. Owens,et al. Patients with attention-deficit/hyperactivity disorder without observed apneic episodes in sleep or daytime sleepiness have normal sleep on polysomnography. , 2005, Sleep.
[52] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[53] Olga V. Demler,et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.
[54] Jae-Chang Jung,et al. Mitogen-Activated Protein Kinase Inhibition in Traumatic Brain Injury: In Vitro and In Vivo Effects , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[55] D. Sheehan,et al. The measurement of disability , 1996, International clinical psychopharmacology.
[56] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[57] M. Hamilton. The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.
[58] F. Artigas,et al. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. , 2015, Pharmacology & therapeutics.
[59] P. Luyten,et al. Diagnostic and Statistical Manual of Mental Disorders , 2015 .
[60] D. Kajdasz,et al. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. , 2008, Primary care companion to the Journal of clinical psychiatry.
[61] D. Sheehan,et al. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. , 2008, Current medical research and opinion.
[62] A. Castaigne,et al. EFFICACY AND SAFETY OF AN ORAL FIXED LOW-DOSE PERINDOPRIL 2 MGDNDAPAMIDE 0.625 MG COMBINATION: STUDY IN ELDERLY PATIENTS WITH MILD TO MODERATE HYPERTENSION A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED , 1999 .
[63] R. Entsuah. Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. , 1996, Journal of biopharmaceutical statistics.